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Abstract 
Objective: Take-home naloxone (THN) reduces deaths from opioid overdose. To increase 
THN distribution to at-risk emergency department (ED) patients, we explored reasons for 
patients’ refusing or accepting THN.  
Methods: In an urban teaching hospital ED, we identified high opioid overdose risk patients 
according to pre-specified criteria. We offered eligible patients THN and participation in 
researcher-administered surveys, which inquired about reasons to refuse or accept THN 
and about THN dispensing location preferences. We analyzed refusal and acceptance 
reasons in open-ended responses, grouped reasons into categories (absolute versus 
conditional refusals,) then searched for associations between patient characteristics and 
reasons.   
Results: Of 247 patients offered THN, 193 (78.1%) provided reasons for their decision. Of 
those included, 69 (35.2%) were female, 91 (47.2%) were under age 40, 61 (31.6%) were 
homeless, 144 (74.6%) reported injection drug use (IDU), and 131 (67.9%) accepted THN. 
Of 62 patients refusing THN, 19 (30.7%) felt “not at risk” for overdose, while 28 (45.2%) 
gave conditional refusal reasons: “too sick”, “in a rush”, or preference to get THN 
elsewhere.  Non-IDU was associated with stating “not at risk,” while IDU, homelessness, 
and age under 40 were associated with conditional refusals. Among acceptances, 86 
(65.7%) mentioned saving others as a reason.  Most respondents preferred other 
dispensing locations beside the ED, whether or not they accepted ED THN.   
Conclusion: ED patients refusing THN felt “not at risk” for overdose or felt their ED visit was 
not the right time or place for THN.  Most accepting THN wanted to save others.  
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Introduction 
In 2016, an unprecedented 2800 Canadians died of opioid overdose (OD),[1]  while 
hospitalization rates and emergency  department (ED) visits for opioid OD have increased 
correspondingly. [2] Take-home naloxone, (THN) consisting of several doses of naloxone, 
single-use instructions, simple rescue breathing masks, and educational brochures, is a 
harm reduction intervention for bystander opioid OD reversal. Dispensing THN to at-risk 
users has reversed over 26,000 OD in the US [3] and decreased opioid-related community 
death rates. [4] Seven of thirteen Canadian provinces and territories have initiatives to 
expand take-home naloxone (THN) access and coverage. [2,5] 
 
Since ED visits and non-fatal ODs are markers for subsequent OD mortality, [3,6,7] EDs 
become an opportune setting to reach those at highest risk.  In North America, EDs 
increasingly dispense THN [8-13] and 70% of ED patients accept THN. [8] While physician 
barriers to ED-based THN dispensation have been reported, [9,12,14] patient-specific 
reasons for ED THN acceptance or refusal have not. In non-ED settings, factors contributing 
to refusals include reluctance to give injections, fear of triggering additional drug use, and 
inappropriate minimization of OD risk. [15-19] Conversely, patients are motivated to 
accept THN if they feel they can help others, [17,19,20] if they have had an OD themselves, 
[18] or if they know a peer with THN. [21]    
 
To improve quality and reach of ED THN distribution and education, it is crucial to gain 
greater understanding of reasons influencing THN refusal or acceptance in ED patients. We 
surveyed high-risk ED patients to explore reasons for refusing or accepting THN. 
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Methods 
Design & Philosophy: The study is a content analysis of open-ended question responses in a 
researcher-administered survey of ED patients with both qualitative and quantitative 
aspects. Quantitative analysis of other survey questions has previously been reported.[8] 
Descriptive qualitative tools borrowed from grounded theory informed the analysis of 
open-ended responses, allowing themes to emerge from respondents’ own words. [22] 
Because use of qualitative tools confers some of the risks and benefits of qualitative 
research, we report methods and results according to the SRQR (Standards for Reporting 
Qualitative Research) format. [23] Our research philosophy is consistent with post-
positivism or pragmatism, [24,25] where we acknowledge and address the subjectivity of 
the research team.  Our design was dictated by the practical need of THN program 
implementers to quickly solicit “real-world” (during an actual ED visit rather than a 
planned focus group) patient input that could be used for program evaluation and 
improvement.  Due to time and space constraints of approaching candidates during their 
ED stay, the survey adopted sampling and analysis strategies that were predetermined and 
not iterative.  For similar reasons, the survey did not contain follow-up questions to open-
ended responses.  As most open ended-responses were short, a count-based quantitative 
approach supplemented the use of qualitative tools.  To facilitate this quantitative analysis, 
consensus building and inter-coder agreement were deemed desirable (contrary to 
qualitative approaches where presenting interpretive disagreements between researchers 
might enhance the analysis.)  Finally, we included some quantitative analysis of previously 
unreported data from closed-ended questions on feeling respected in the ED and on 
preferred locations for THN dispensing: We felt these data were complimentary to the 
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open-ended questions.   
Context:  The study took place at St Paul’s Hospital ED in Vancouver, British Columbia.  
Many of the 85,000 annual patients have unstable housing, mental illnesses, and substance 
use disorders, including injection drug use (IDU). The province of British Columbia is home 
to North America’s first officially sanctioned supervised drug injection site [26] and 
Canada’s first provincial THN program.[19] Shortly before the study, the ED became an 
approved dispensing site for the provincial THN program: ED staff offered THN to at-risk 
patients and gave standardized THN training lasting approximately 5 minutes. During the 
study, research assistants (RAs) offered eligible patients THN (as part of the provincial 
program) and survey participation simultaneously.  RAs were non-physicians who had no 
direct patient care involvement.  All RAs had an ED orientation, an introduction to harm 
reduction principles and an opportunity to pilot the study before beginning study work. 
Regular ED staff continued to train patients and dispense THN to those interested, 
regardless of study participation.   
Sampling Strategy: RAs screened candidates using triage notes and printouts of the last 6 
months of the provincial pharmacy database. The following patients were approached: (a) 
self-reported opioid use at triage or during pre-hospital care, (b) clinical opioid OD or 
withdrawal, (c) prescriptions of methadone, buprenorphine/naloxone, or other opioids 
exceeding 100 morphine equivalents daily, (d) injection-related infections, and (e) narcotic 
requests (defined as the chief complaint including a request for a refill of previous opioid 
prescription). ED staff could refer additional study candidates to the RAs.  RAs invited 
consecutive eligible patients to participate, and excluded patients too ill, agitated, or 
sedated to answer study questions or undergo THN training.  Those who already had a 
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THN kit were ineligible.  The rationale for selecting a target sample size of 200 was based 
on the previously reported quantitative outcome-based component of the study.[8] 
Ethics, consent, & permissions: All participants provided written informed consent, could 
choose a suitably private ED interview location, and could receive THN regardless of 
survey participation.  Age range, gender, and eligibility criteria met were recorded without 
personal identifiers for study candidates who declined participation or who met exclusion 
criteria.  The University of British-Columbia-Providence Health Care Research Ethics Board 
(H14-03430) and the London School of Hygiene & Tropical Medicine (MSc Ethics 8673) 
approved the study. 
Data Collection:  RAs covered pre-specified 4-to 8-hour shifts in a 2:1 daytime to evening 
ratio including weekends from May to August 2015, and administered the survey 
(Appendix)[8] to consenting patients after medical stabilization.  RAs asked patients about 
demographics, substance use, and THN-related preferences, as well as an open-ended 
question on the reason for accepting or refusing THN.  Participants who had difficulty 
answering open-ended questions were provided with “prompts”: a menu of possible 
answers (see Appendix) containing themes previously cited in the harm reduction 
literature and by content experts including patients and addiction specialists.  Patients 
completing the standardized 15 – 20 minute survey received $10 compensation.  RAs 
entered verbatim (in the patient’s voice) responses into anonymous electronic survey 
forms (Surveymonkey.com, Palo Alto, CA.) Responses were later transferred to Excel 
version 14.7.1 (Microsoft, Redmond, WA) and STATA version 11.0 (StatCorp, College 
Station, TX) for further analysis.  During data collection, RAs regularly communicated with 
each other and with the study leads to clarify uncertain points or conflicting data. 
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Data analysis: We analyzed open-ended question responses by developing a coding 
structure for reasons to accept or reject THN.  The primary coder was an RA who analyzed 
the open-ended responses as part of her master’s thesis. The primary coder and one senior 
researcher initially independently coded the same random 20% subset of responses, then 
met to discuss their coding structure with a qualitative research methodologist to generate 
consensus for a codebook.  The primary coder then applied the codebook to the complete 
data set, adding additional codes where needed. A secondary coder not involved in the 
initial coding or interviews analyzed the data using the codebook. The two coders’ 
selections were compared for inter-coder reliability, with full code matching required if a 
response had more than one code assigned. A discussion between coders, moderated by a 
senior researcher, generated further consensus, leading to a measure of inter-coder 
agreement.[27] If disagreement between coders persisted, the senior moderator’s chosen 
code was used for further analysis. [27].  In order to test associations of patient 
characteristics with specific reasons for THN acceptance or refusal, we classified 
characteristics by the following pre-specified mutually exclusive subgroups: male/female, 
IDU/non-IDU, no fixed address (homeless)/fixed address, and age over 40/age under 40. 
Reasons mentioned in 10% or more of refusals or acceptances were tested for association 
with patient characteristics.  In order to facilitate some quantitative analysis of reasons 
mentioned by fewer than 10% of respondents, we included these responses into larger, 
mutually exclusive, binary category groupings by identifying overarching themes.  We then 
tested these categories for association with patient characteristics.  Reasons for THN 
refusal were classified into the categories absolute (not interested in THN at all) or 
conditional (potentially interested in THN but not desiring it during this ED visit.) Reasons 
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for THN acceptance were classified into the following categories: either mentioning a 
desire to help others, or not mentioning this desire.  To test for potential confounding, 
patient characteristics were checked for association with other patient characteristics.  We 
used Fisher’s exact test for testing all associations, with p = 0.05 as a threshold for 
significance. Responses to closed-ended questions on feeling respected in the ED and on 
THN preferences were analyzed with descriptive statistics only.  
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Results 
We identified 417 consecutive THN candidates and offered 247 eligible patients THN and 
survey participation, of whom 193 (78.1%) completed the open-ended questions on THN 
acceptance and were analyzed. (Figure 1) Participant characteristics, as well as those of 
patients excluded or refusing participation, are presented in Table 1.  Interviewers used at 
least one prompt for approximately a quarter of the patients. The coding process identified 
10 reasons for refusal and 12 reasons for acceptance, which were grouped into mutually 
exclusive binary response categories. (Table 2)  Associations between patient 
characteristics and types of responses are presented in Table 3.  Inter-coder reliability was 
74.9% (95% CI 68.7 to 81.0%, N=191 because 2 originally misclassified responses were not 
included in the calculation) and inter-coder agreement after discussion was 95.3% (95% CI 
92.3 to 98.3%, N=191 as above.) 
Reasons for refusing THN  
Sixty-two patients provided reasons for refusing THN. (Table 3 for all results below unless 
otherwise mentioned.) “I’m not at risk” was the most common, mentioned by 30.7% (95% 
CI 19.2-42.2%) of patients refusing. IDU patients expressed this reason significantly less 
frequently than non-IDU patients. Some participants taking prescription opioids gave 
additional details related to risk perception: “I’m just not interested. I don’t believe I will 
truly OD because my doc has close eye on my meds.” Other reasons for absolute refusals 
included  “Encourages abuse,” “Would not use,” “Uncomfortable with injections,”  “Done with 
drugs,“ and passive suicidality. (Table 2)  When refusing THN, women endorsed “Done with 
drugs” three times as frequently as men, a statistically significant difference. Of 62 patients 
refusing THN, 48 (45.2% [95% CI  32.8 to 57.6%]) endorsed the following conditional 
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reasons: “Poor timing,” “In a rush,” “Too sick” and preference for another location.  Patient 
characteristics significantly associated with conditional refusals were age younger than 40, 
homelessness, and IDU status. 
Reasons for Accepting THN 
“Save someone else’s life” was the most common acceptance reason, mentioned by 65.6% 
(95% CI 57.4 to 73.9%) of patients accepting THN, followed by “Save my own life” by 35.1% 
(95% CI 26.8 to 43.4%,) with 22.1% (95% CI 15.0 to 29.2%) of patients stating both 
reasons.  Age under 40 was significantly associated with the “Save my own life” reason for 
accepting THN. One accepting patient also mentioned feelings of potential self-harm: 
“Because I’ve thought about suicide by an overdose so it would be safe to have one around 
in case I change my mind.” The acceptance category “for self,” encompassing all acceptance 
responses not specifically mentioning the desire to help others, was not associated with 
any particular patient characteristic. (Table 3) 
Preference for other THN distribution locations & feeling respected 
Overall, 155 patients (including those refusing and accepting THN) answered a closed-
ended question on THN location preference.  Of these, 117 (75.5% [95% CI 68.6 to 82.3%]) 
preferred non-ED sites. The supervised injection site was the most frequently preferred 
location for THN distribution, followed by the ED, then in descending order of preference 
community clinics, family doctors, methadone doctors, pharmacies, and their own 
apartment buildings. THN location preference was not associated with specific open-ended 
response reasons for refusing or accepting THN, other than “Prefers other location.” Nine 
patients expressed “Prefers other location” as a reason for refusal in open-ended responses, 
though only one mentioned a specific reason (“not a hospital fan.”) Of the overall study 
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cohort, 36.8% of patients felt inadequately respected in the ED.  This lack of respect was 
not significantly associated with preference for a non-ED THN location, conditional 
refusals, or refusing THN overall. 
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Discussion 
In this survey of 193 ED patients at risk of opioid overdose, we identified key reasons for 
refusal and acceptance of THN. While understanding motivators of THN acceptance is 
important, understanding barriers is critical: Our findings may help physicians overcome 
the reluctance of vulnerable ED patients to accept a life-saving intervention.  
 
The most common reason for refusal was feeling “not at risk” for OD.  Some patients 
expressed confidence they would not overdose if taking opioids only as prescribed by their 
physician, as previously noted in patients on opioids for chronic pain.[19] Unfortunately, 
patients taking prescription opioids are at increased overdose risk, proportional to 
increasing opioid doses.[28] Conversely, our IDU patients less frequently mentioned “not at 
risk” as a reason for refusing THN, suggesting they might be more aware of overdose risk.    
The reasons “done with drugs” and “encourages abuse” arose in our study population, 
mirroring concerns elsewhere that THN kits with syringes could increase risky behavior or 
trigger opioid use relapses. [15-17] Nevertheless, THN program participation has been 
associated with decreased (rather than increased) high-risk opioid use.[29]   
 
Both patients accepting and refusing THN mentioned thoughts of suicide or not caring 
whether they overdosed.  This is not surprising given the high correlation of opioid use 
disorder and depression[30] and previously reported associations between opioid 
overdoses and suicidal ideation, [31] further highlighting the need for integration of 
addiction and mental health care.  Though “not being comfortable with injections” has been 
noted in other populations, [16] our patients, the majority of whom injected drugs, did not 
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mention this barrier often.  
 
Conditional refusals are critical as they imply patients who might be ready for THN 
acceptance, although not during that particular ED encounter. Conditional refusals were 
associated with younger patients and those experiencing homelessness, although neither 
characteristic was associated with lower THN acceptance overall.[8] Among specific 
reasons for conditional refusals, patients cited “too sick,” “in a rush,” and “poor timing,”  all 
previously unreported in community settings.  These reasons may not be surprising in an 
ED setting where patients are acutely ill and do not present specifically seeking harm 
reduction services.   Some previously identified barriers to accepting THN were not directly 
mentioned by our study population, notably fear of interacting with police and drug-related 
stigma. [16,19] 
 
The most common motivator for THN acceptance was helping others, reflected in 
responses about saving other and educating others.  This desire is also common in non-ED 
settings.[17,19,20] Wanting to protect oneself from OD or to generally “feel safer” 
corroborates with prior quantitative analysis of our study cohort: Those concerned about 
their own OD risk were more likely to accept THN.[8] One participant mentioned peer 
influence, a strong driver of THN acceptance elsewhere. [21] The “feels good” reason 
mentioned by another reminiscent echoes the feeling of personal empowerment cited by 
other THN research [19,20]. 
 
The THN acceptance reasons  “did not know where to get one,” “willing to try,” “never had 
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one,” “lost other kit,” and “supervised injection site crowded” highlight the convenience of 
ED dispensing. Prior analysis of our study population indicates that 80% of patients felt the 
ED was indeed a convenient setting for THN. [8] Taken together, these findings further 
support the concept of the ED as a 24-hour location for patients who might not otherwise 
have easy THN access.  
 
Preferences for THN dispensing sites have not been previously reported.  Even among 
accepting patients, the community’s supervised injection site was the preferred location.   
Many factors may play into this preference, including the dislike of hospitals mentioned by 
one participant.  Nevertheless, lack of feeling respect in the ED, previously noted in another 
marginalized ED population [32], did not appear to play a significant role in patient’s THN 
location preferences or in their reasons for refusing THN.      
 
Importantly, our findings may encourage ED THN programs to adopt strategies to enhance 
uptake. ED staff should gently emphasize true OD risk in a non-judgmental manner. 
Secondly, staff should empower patients by encouraging THN acceptance to help other at-
risk peers. For patient convenience, THN needs can be addressed early in the ED stay in 
parallel with medical management. Even if patients refuse THN in the ED, providers should 
emphasize the importance of THN kits and encourage patients to discuss it in the 
community with family, peers, and trusted care providers. The presence of a dedicated 
nurse, social worker, or other care provider specially trained in addictions treatment in the 
ED would likely enhance patient receptivity to both THN and other forms of addictions care 
and harm reduction. 
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Limitations 
Our findings at a single inner-city centre with a high proportion of IDU may be challenging 
to extrapolate to other settings, but the themes found in our population are congruent with 
those in non-ED environments. The analysis of open-ended question responses is 
necessarily limited due to a sampling strategy based on the survey’s quantitative design. 
Traditional qualitative approaches such as iterative interviewing and theory development 
could have helped clarify responses, explore additional reasons, and assess theme 
saturation.  Social desirability bias may have occurred in the context of compensation for 
participation, though the candor of responses suggests such bias to be minimal. Lack of 
interview recording could have allowed RAs to inject their own words into transcriptions.  
Interviewer prompting could have directed participants’ responses in some cases by 
providing a quick and easy answer rather than one in an authentic patient voice.  Some 
subgroups, especially those involving patients refusing THN, are small and could draw 
spurious associations or fail to identify correct ones.   
 
Conclusion 
ED patients refusing THN either did not feel at risk for OD or did not feel their ED 
encounter was the right time and place for THN.  Most ED patients accepting THN wanted 
to save others from OD.  
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Figure 1: Study flow diagram 
 
 417 potential take-home naloxone (THN) candidates identified  
during 601 hours of study enrollment in the emergency department (ED) 
170 patients excluded 
 
41 left ED prior to being approached by research staff 
62 with acute illness precluding consent and participation 
    55 had altered level of consciousness (too sedated, agitated, psychotic) 
    7 too acutely ill to participate 
23 unable to own or use THN (institutionalized, incarcerated, too physically or 
cognitively impaired) 
16 previously enrolled in study 
12 denied opioid use in last 6 months 
13 already had THN kit 
2 protocol violations (1 age < 16, 1 not emergency department patient) 
1 other (did not speak sufficient English for survey) 
 
 
 
  
 
247 offered THN and survey 
54 did not complete survey  
  40 declined survey participation 
  14 did not provide reason for their decision on THN 
 
193 patients completed survey and were included in analysis 
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Table 1: Patient Characteristics, including those declining study participation or excluded  
Characteristic 
Included 
N=193 
Declined 
N=54 
Excluded 
N=170 
Fisher’s 
exact § 
 # (%) 95% CI # (%) 95% CI # (%) 95% CI  
Demographics       
 
Female 
69 
 (35.2) 
28.6-42.2 
22  
(40.7) 
27.2-54.3 
66  
(38.8) 
31.4-46.2  
Under age 40 
91  
(47.2) 
40.0-54.3 
20  
(37.0) 
24.1-49.9 
84  
(49.4) 
41.9-56.9  
Indigenous 
47 
(24.7) 
18.5-30.9 -- -- -- --  
Homeless 
61  
(31.6) 
25.0-38.2 -- -- -- --  
Opioid Use        
IDU* 
144 
(74.6) 
68.4-80.8 -- -- -- --  
IDU from triage 
screening* 
85  
(44.0) 
37.0-51.1 
24  
(44.4) 
30.8-58.1 
75  
(44.1) 
36.6-51.7  
Methadone or 
Suboxone prescription  
86 
 (44.6) 
37.5-51.6 
25  
(46.3) 
32.6-60.0 
70 
 (41.2) 
33.8-48.9  
High-dose opioid 
analgesic prescription** 
31 
 (16.1) 
10.8-21.3 
8  
(14.8) 
5.0-24.6 
13 
 (7.6) 
3.6-11.7 P=0.040 
ED presentation        
Opioid overdose 
29 
(15.0) 
9.9-20.1 
16  
(29.6) 
17.0-42.2 
36  
(21.2) 
15.0-27.4 P=0.043 
Other opioid-related 
chief complaints *** 
58  
(30.1) 
23.5-36.6 
12  
(22.2) 
10.8-33.7 
38  
(22.4) 
16.0-28.7  
Non-opioid-related 
chief complaints 
106 
(54.9) 
47.8-62.0 
26  
(48.1) 
34.4-61.9 
96  
(56.5) 
48.9-64.0  
Outcome        
Take-home naloxone 
acceptance 
131 
(67.9) 
61.2-74.5 -- -- -- -- -- 
ED respect & THN location preferences      
Does not always feel 
respected in ED 
73 
(36.8) 
29.9-43.7 -- -- -- -- -- 
Prefers THN dispensing 
location other than ED# 
117 
(75.5) 
68.6-82.3 -- -- -- -- -- 
§difference between three groups significant at 95% level by Fisher’s exact test 
*IDU:  injection drug use; “IDU from triage screening” refers to IDU reported in triage documents only 
**prescription data obtained from print-out report of last 6 months from provincial pharmacy database 
***other opioid related chief complaints include soft-tissue infection consistent with IDU, withdrawal, and opioid request 
-- data unavailable for patients refusing or excluded 
#N=155 
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Table 2: Participants’ reasons codes and categories, with illustrative quotes & frequency  
Code Reason  
Frequency 
# (%)§ 
Reason 
Category 
 Refusing THN  Illustrative quotes 62 (100.0)  
8  Not at risk “I know my limit so I don't need a Narcan kit.” 19 (30.7) Absolute 
2 Done with drugs 
“Right now I'm going to detox and I don't need opioids or anything related to 
opioids in my life anymore.” 
11 (17.7) Absolute 
3  Too sick 
“I'm not in the best shape right now and I wouldn't want to miss anything important 
in the training so I'll do it another day” 
11 (17.7) 
Condition
al 
6 Prefers other location “I can also get a kit from work or other places because I know where to go.” 9 (14.5) 
Condition
al 
1  In a rush “I've been here a long time and I want to get going.” 6 (9.7) 
Condition
al 
4 Poor timing “I just got released from the hospital and it's not a good time to take one.” 6 (9.7) 
Condition
al 
9  Would not use “I am not around people who use drugs” 5 (8.1) Absolute 
5 
Uncomfortable giving 
injections 
“I wouldn't want to inject someone with a kit - not comfortable doing that.” 2 (3.2) Absolute 
7 Encourages abuse “ I feel like these kits would be abused. Gives people an excuse to use more.” 2 (3.2) Absolute 
10  Passive suicidality “I just don’t care.” 2 (3.2) Absolute 
 Conditional category 
Reason based on time and place, mutually exclusive of any response mentioning 
absolute reason 
28 (45.2)  
     
 Accepting THN Illustrative quotes 131 (100.0)  
2 
Save someone else’s 
life 
“My brother is at risk of dying of an overdose and I want to help him.” 86 (65.7) 
For 
others 
3 Save my own life “So I don't overdose when I shoot up.” 46 (35.1) For self 
1 General safety “Just in case. To be safe.”  “It’s a good thing to have.” 20 (15.3) For self 
8 Willing to try “Just to try it out.” “Why not?” 3 (2.3) For self 
7 
Did not know where to 
get one 
“Always thought it would be a good idea to have one but I didn't know where I 
could go to get one.” 
1  (0.8) For self 
4 Never had one “Never had one before and it would be good to have one around.”* 1 (0.8) For self 
5 Educate others “Show people the kits and tell my friends they are available” 1 (0.8) 
For 
others 
6 Lost other kit “Lost my old one and want it just in case I overdose in the future.”** 1 (0.8) For self 
10 
Supervised injection 
site crowded 
“Insite# is always busy so it would be a good thing to have around.” 1 (0.8) For self 
9 Peer impact “Heard about it and saw someone with a kit.”   1 (0.8) For self 
11 Feels good “Always like having one. Actually feels bad not having one.” 1 (0.8) For self 
12 
Everyone should have 
one 
“We should all have one. I want one because I need one and everyone should carry 
it with them.” 
1  
(0.8) 
For self 
 For self category 
Reason not mentioning others, mutually exclusive of any response mentioning 
desire to help others 
44 (33.6)  
§Frequency sum greater than 100% because some responses included more than 1 reason 
* Response also counted as acceptance code 1, ** Response also counted as acceptance code 3 #Supervised drug injection site 
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Table 3: Association of participant’s responses with participant characteristics 
Reasons for 
refusing THN 
Female 
N=16* 
Male 
N=45* 
IDU 
N=38 
No IDU 
N=24 
NFA 
N=18 
Not NFA 
N=44 
Age ≥40 
N=33 
Age <40 
N=29 
# (%) Participants expressing reason by selected characteristics 
 Not at risk 
6 
(37.5) 
13 
(28.9) 
6** 
(15.8) 
13** 
(54.2) 
3 
(16.7) 
16 
(36.4) 
13 
(39.4) 
6 
(20.7) 
Done with drugs 
6** 
(37.5) 
5** 
(11.1) 
6  
(15.8) 
5 
(20.8) 
1  
(5.56) 
10  
(22.7) 
7 
(21.2) 
4 
(13.8) 
 Too sick 
3 
(18.8) 
7 
(15.6) 
7 
(18.4) 
4 
(16.7) 
4 
(22.2) 
7 
(15.9) 
4 
(12.2) 
7 
(24.1) 
Prefers other 
location 
2 
(12.5) 
7 
(15.6) 
7 
(18.4) 
2 
(8.3) 
4 
(22.2) 
5 
(11.4) 
3 
(9.1) 
6 
(20.7) 
Conditional 
reason category 
6  
(37.5) 
21  
(46.7) 
22** 
(57.9) 
6** 
(25.0) 
12**  
(66.7) 
16**  
(36.4) 
10** 
(30.3) 
18** 
(62.1) 
         
Reasons for 
accepting THN 
Female 
N=52 
Male 
N=79 
IDU 
N=106 
Non-IDU 
N=25 
NFA 
N=43 
Non-NFA 
N=88 
Age ≥40 
N=69 
Age <40 
N=62 
Save someone 
else’s life 
34  
(65.4) 
52 
(65.8) 
70 
(66.0) 
16 
(64.0) 
26 
(60.5) 
60 
(68.2) 
46 
(66.7) 
40 
(64.5) 
Save my own life 
18 
(34.6) 
28 
(35.4) 
36 
(34.0) 
10 
(40.0) 
16 
(37.2) 
30 
(34.1) 
18** 
(26.1) 
28** 
(45.2) 
General safety 
9 
(17.3) 
11 
(13.9) 
17 
(16.0) 
3 
(12.0) 
7 
(16.3) 
13 
(14.8) 
11 
(15.9) 
9 
(14.5) 
For self reason 
category 
18 (34.6) 26(32.9) 35 (33.0) 
9 
(36.0) 
17(39.5) 27 (30.7) 23 (33.3) 21 (33.9) 
* 1 participant identifying as “other” gender not included in analysis  **P<0.05 by Fisher’s exact test 
Characteristics from Table 1 not associated with specific reasons for accepting or refusing are not shown:  Indigenous, 
methadone or buprenorphine prescription, high-dose opioid analgesic prescription, and type of ED presentation 
IDU: Injection drug use; NFA:  No fixed address (homeless) 
Variables Age < 40, IDU, and NFA were all associated with each other by Fisher’s exact test (p<0.05) 
 
 
